Dr. Reddy's Laboratories has agreed to acquire a select portfolio of the established products business of UCB, in the territories of India, Nepal, Sri Lanka and Maldives. The acquired business is being sold on a slump sale basis. The transaction includes approximately 350 employees engaged in operations of the India business. The revenues of the acquired business is approximately INR 150 Crores for calendar year 2014.

The acquisition of UCB's existing brand equity in the areas of dermatology, respiratory and pediatrics diseases will further expand Dr. Reddy's therapy footprint into these areas. The transaction is expected to be closed in the first quarter of the financial year 2015-16.

Source: Dr. Reddy’s Laboratories